CS MEDICA A/S (“CS MEDICA or the company”) has entered a joint venture with Inner Mongolia RongShi Hi-Tech Co., Ltd (“RongShi”) regarding production of CS-Medica’s CANNASEN® CBD medical products in China and distribution of CANNASEN® CBD products to the Asian market. The Joint Venture has been registered in Ordos, Inner Mongolia, China

Lone Henriksen, CEO CS MEDICA, comments;

“With this JV agreement and business license in China we are stepping into a whole new area of the CS MEDICA. Together with RongShi we now have the necessary capacity in CS MEDICA to penetrate the Asian market with our CANNASEN®CBD medical products. I am truly looking forward to our cooperating with Mr. Gao (Jason), and with Guo Longlong (Harry), our Asian Director, who will be responsible for the Asian market. I am sure we together will reach new heights with the JV as well as for CS MEDICA”.

From Left: Mr Gao(Jason), Legal owner & General Manager, Inner Mongolia RongShi Hi-Tech Co., Ltd, Lone Henriksen, CEO, CS MEDICA A/S

Joint Venture
The JV will be a production company facilitating the production and delivery of the CANNASEN® product line to the Asian market.

CS MEDICA will deliver all knowhow related to the acquisition and installation of the production line, as well as product related quality assurance according to GMP & ISO 13485 and approvals associated to the ongoing production. Furthermore, CS MEDICA will deliver all product and production instructions related to the ongoing production.

RongShi will be responsible for the funding related to the purchasing of land, building construction, equipment, and the installation of the production lines including gel line, patch line and inhaler line in Erdos High Tech Zone. After finalizing the installation, the JV will be responsible for the ongoing production processes according to instructions from CS MEDICA.  Furthermore, RongShi will handle all coordination with and approvals by legal authorities related to the product line installation and commissioning.

First Board meeting and the Registration of the JV
According to the provisions of PR. China’s “Company Law”, the two shareholders, CS MEDICA and RongShi, of the Joint Venture held their first board meeting Thursday the 23^th of March 2023, with following resolutions:

1. Agree to approve the Articles of Association of Rongshi Medica (Ordos) Co., Ltd.;

2. Agree that the board are represented by Mr Xue (board member), Lone Henriksen (board member) and Mr. Gao (Jason) (Chairman of the board), Mrs. Su (Supervisor)

3. Agree to establish the JV under the name “Rongshi Medica (Ordos) Co., Ltd.”

4. Agree to appoint Mr. Gao (Jason) as the general manager (legal representative).

5. Agree to establish the JV production in the High-Tech Zone of Erdos.

6. Agree to distribute the CANNASEN®CBD medical products and cosmetic in Asia excluding India – starting with cosmetic in Thailand and Japan.

From Left: Mr. Xue (Board member), Mr. Guo (Harry) (Asian Director – CS MEDICA). Mrs. Su (Supervisor), Gitte Lund Henriksen (CFO – CS MEDICA), Lone Henriksen (CEO – CS MEDICA & Board member), Mr. Gao (Jason) (Chairman of board & General Manager).

Mr Gao(Jason) General Manager of Rongshi Medica (Ordos) Co., Ltd., said,

“RongShi not only invests CS MEDICA in Denmark, but also setup “Rongshi Medica (Ordos) Co., Ltd.” in my hometown Erdos because I, my partner Mr. Xue and my team believe that the medical cannabis and CBD medical products will have a huge potential in the following 5 years in the market of China and other Asian countries. Today in China hemp growing cover more than 50% of the global production of Hemp, and many extraction companies produces CBD using CO2 extraction technology. These kinds of companies are located in Yunnan province and Heilongjiang Province, China. With the Joint Venture we differentiate from these hemp growers and extraction companies. We only focus on the CBD medical devices products approved by local FDA. This will reduce the risk for “Rongshi Medica (Ordos) Co., Ltd.” and CS MEDICA. We believe our cooperation will be success to reach the win-win.”

Lone Henriksen, CEO CS MEDICA & Board Member of Rongshi Medica (Ordos) Co., Ltd, continues:

“We believe that RongShi & CS MEDICA is a very good match, as RongShi provide funding, investment, local network & business knowledge in Asia, whereas CS MEDICA provides the technology, quality assurance & registrations. We look forward to our very first exhibition at the Global pharmaceutical exhibition CPHI in Tokoy Japan April 19 – 21, 2023, where Rongshi Medica (Ordos) Co., Ltd. Participate together with CS MEDICA.”

Business license obtained
Friday the 24^th of March 2023, the JV was registered with the name RongShi Medica (Ordos) Ltd., with a registered capital of 50 million CNY (DKK 50,4 million). “Rongshi Medica (Ordos) Co., Ltd.” ownership is divided with 51% to RongShi and 49% to CS MEDICA.

From left: Mr. Guo (Harry) (Asian Director – CS MEDICA), Lone Henriksen (CEO – CS MEDICA & Board Member), Gitte Lund Henriksen (CFO – CS MEDICA), Mr. Gao (Jason) (Chairman of the Board & General Manager), Mr. Xue (Board member).

Friday the 24^th of March 2023,  the JV obtained their business license at the Ordos Local government.

Erdos  High Tech Zone
Erdos High-tech zone, a state-level hi-tech zone, is managed by Erdos government and covers an area of 270.6 square kilometers. It has four parks including Hi-Tech industry park, equipment manufacturing industry park, textile industry park and auto expo park with more than 2000 companies registered. Erdos Hi-Tech Zone is an important platform for Erdos industrial transformation and the main carrier of scientific and technological innovation.

The JV production lines will be the third pharmaceutical company located in the bio-Pharmaceutical part of Hi-Tech industry park of Erdos Hi-Tech Zone, and will receive different types of the policy supports from Erdos Hi-Tech Zone, such as technology project funding, patent funding, 5 years free tax, 3 years free-office and apartments, etc in the beginning of JV. The local government will help JV growing better and better.

This disclosure contains information that CS MEDICA A/S is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 26-03-2023 19:09 CET.

For more information about CS MEDICA, please contact:
Lone Henriksen, CEO
Phone: + (45) 71 20 30 47
Email: lh@cs-medica.com
Website: https://www.cs-medica.com/

CS MEDICA A/S is a Danish-based MedTech company operating within research, development, manufacturing, commercializing, and a part of the pharmaceutical industry. The company combines science and nature with the purpose of creating products for a better every day by using modern technology to research and utilize different compounds found in the cannabis plant. CS MEDICA offers efficient, safe OTC alternative treatments for autoimmune and stress-related disorders under the trademark CANNASEN® or own label options.

The company is listed on Spotlight Stock Market in Stockholm (symbol: “CSMED”). more information, visit cs-medica.com, and LinkedIn.

https://news.cision.com/cs-medica-a-s/r/cs-medica-has-entered-a-joint-venture-regarding-production-of-cs-medica-s-cannasen–cbd-medical-prod,c3740838

https://news.cision.com/cs-medica-a-s/i/lone-signing-original-edit,c3160057

https://news.cision.com/cs-medica-a-s/i/signing,c3160058

https://news.cision.com/cs-medica-a-s/i/jv-reg,c3160059

https://news.cision.com/cs-medica-a-s/i/business-proff,c3160060

(c) 2023 Cision. All rights reserved., source Press Releases – English

The partnership will enable Puro to become a data-led cannabis cultivator, streamline its operations & adhere to the highest pharmaceutical standards.

MARLBOROUGH, New Zealand & VANCOUVER, British Columbia–(BUSINESS WIRE)–#ERP—Puro, New Zealand’s largest and most successful cultivator of medicinal cannabis, has selected Elevated Signals as its manufacturing execution system (MES). Following a rigorous procurement process that evaluated multiple seed-to-sale and track & trace systems worldwide, Puro chose Elevated Signals for its ability to streamline operations, manage data collection, and ensure compliance with pharmaceutical standards.

Elevated Signals replaces systems of spreadsheets, paper, and outdated software with a fully-digital centralized platform that manages inventory, quality recordkeeping, compliance and environmental data. Its GMP-validated system enables significant improvements to supply chain visibility, operational productivity, and yield optimization, ultimately increasing profitability for cannabis producers.

Tom Forrest, Co-founder & Cultivation Director of Puro, said, “at Puro, our focus is on cultivating the highest quality medicinal cannabis. In order to do this, we have to implement the best-in-class systems throughout our operation. Collecting data is crucial not only to achieve the best outcomes in cultivation but also to guide our decision-making and improve the productivity of our team. Elevated Signals will enable us to digitally track the entire life cycle of our crops, ensuring compliance at every stage. Both in terms of the superiority of the product and the ethos of their team, it was clear that Elevated Signals was the perfect fit for us.”

Amar Singh, Co-founder & CEO of Elevated Signals, said, “our platform was built and battle-tested in Canada, the world’s most stringent cannabis market, and is now used by top producers internationally. We’re dedicated to bringing best practices in operational excellence to cannabis businesses across the globe, so we’re thrilled to be expanding into the emerging market of New Zealand through our partnership with Puro and its talented team.”

In 2022 Puro was awarded a grant for NZD 13 million (CAD 11 million) from New Zealand’s federal government to help fast-track the country’s organic medicinal cannabis industry. Under the agreement, Puro will develop production systems, support skills and training, explore contract growing and identify pathways to market for industry growth. Elevated Signals’ system will play a key role in helping Puro build a comprehensive blueprint for cannabis best practices in New Zealand.

About Elevated Signals

Elevated Signals provides advanced manufacturing software for the cannabis industry. Headquartered in Vancouver, Canada, it is used by some of the largest cannabis operations in North America, as well as mid-sized and craft cultivators and processors worldwide. By replacing fragmented systems of spreadsheets, paper, and outdated seed-to-sale software with a fully-digital central platform, Elevated Signals unlocks supply chain visibility, operational productivity, and yield optimization, ultimately increasing profitability. More information: https://www.elevatedsignals.com/

NZ medical cannabis company Eqalis has inked an agreement with Australia’s Novachem to bring Eqalis medicinal cannabis products into the Australian market.

Established in 2019, Bay Of Plenty based Eqalis has a GMP certified manufacturing facility in Katikati, which is licensed to produce cannabis-based active ingredients and finished medicines. The company also has two outdoor cannabis cultivation facilities.

The agreement between Eqalis and Novachem will enable the distribution of the former’s active pharmaceutical ingredients (API) and finished products to Australian manufacturers, pharmacies and patients. It’s expected exports from Eqalis to Australia will kick off this year, pending a green light from New Zealand’s Medicinal Cannabis Agency.

“Australia is a leading market for cannabis-based medicines, and we’re thrilled to be a first mover across the Tasman as we cater to demand for our high quality, affordable product to a broader market,” said Eqalis Managing Director Greg Misson.

Novachem’s Cannabis Products and Business Development Manager Andrew Heath said the agreement was a fantastic opportunity for all involved.

“Australian regulations and controls restrict Australian distribution companies sourcing finished products for wholesale supply,” said Mr. Heath. “Our ability to sponsor and provide the Eqalis product for patients in Australia is a win-win trans-Tasman partnership.”

Beyond Australia, Eqalis has its sights set on other jurisdictions as well, with “several” deals in its pipeline that the company expects to announce in the months ahead.

“As more countries legislate for medicinal cannabis products, we are gearing up to provide our API and finished products to patients across the world,” said Mr. Misson.

It’s certainly been a busy time for Eqalis.

In December last year, we reported the firm had signed a binding term sheet with another NZ medical cannabis company, Cannasouth Limited (NZX:CBD), concerning a 50:50 merger between the two companies. It appears that deal is still moving along.

“Together Cannasouth and Eqalis have greater ability to shape the New Zealand industry and make an impact offshore, which we’re incredibly excited about as we focus on reducing costs and delivering better outcomes for patients,” said Mr. Misson.

Mr. Misson says the combined strengths of the companies will bring true vertical integration, with the result being a substantial lowering of costs to patients using medicinal cannabis.

More Kiwi Medical Cannabis Heading To Australia